AI Engines For more Details: Perplexity Kagi Labs You
Arrhythmia Management: Moricizine hydrochloride is effective in treating various types of ventricular arrhythmias, including ventricular tachycardia and ventricular fibrillation. These arrhythmias can be life-threatening and may lead to sudden cardiac arrest if not properly managed.
Proarrhythmic Effects: While moricizine hydrochloride can be effective in suppressing ventricular arrhythmias, it also has proarrhythmic effects, meaning it can potentially worsen existing arrhythmias or induce new arrhythmias. Patients taking moricizine hydrochloride require careful monitoring of their heart rhythm and may need dose adjustments or discontinuation of the medication if proarrhythmic effects occur.
QT Prolongation: Moricizine hydrochloride can prolong the QT interval on the electrocardiogram (ECG), which is a marker for increased risk of ventricular arrhythmias, including torsades de pointes. Patients with preexisting QT prolongation or other risk factors for arrhythmias should be closely monitored while taking moricizine hydrochloride.
Hemodynamic Effects: Moricizine hydrochloride may have hemodynamic effects, including lowering blood pressure and slowing heart rate. Patients with underlying cardiovascular conditions such as heart failure or bradycardia may require careful monitoring and dose adjustments to prevent adverse effects.
Side Effects: Common side effects of moricizine hydrochloride include dizziness, lightheadedness, fatigue, nausea, and vomiting. These side effects are usually mild and transient but may necessitate dose adjustments or discontinuation of the medication in some cases.
Drug Interactions: Moricizine hydrochloride may interact with other medications, particularly other antiarrhythmic drugs and medications that affect heart rhythm. Patients should inform their healthcare providers about all medications, supplements, and herbal products they are taking to avoid potential drug interactions.
Contraindications: Moricizine hydrochloride is contraindicated in patients with certain medical conditions, including severe heart failure, severe bradycardia, second- or third-degree atrioventricular block, and preexisting QT prolongation. It should also be used with caution in patients with hepatic impairment, as it is metabolized in the liver.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 3.4 | 3.4 | |
Age-Related Macular Degeneration and Glaucoma | 0.5 | -0.5 | |
Allergic Rhinitis (Hay Fever) | 1.1 | 1.1 | |
Allergies | 1.2 | 1.3 | -0.08 |
Allergy to milk products | 1 | 0.6 | 0.67 |
Alopecia (Hair Loss) | 1 | 1 | |
Alzheimer's disease | 1.9 | 1.9 | 0 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 0.6 | 1.67 |
Ankylosing spondylitis | 2 | 0.9 | 1.22 |
Anorexia Nervosa | 0.5 | 0.9 | -0.8 |
Antiphospholipid syndrome (APS) | 1.4 | 1.4 | |
Asthma | 0.5 | -0.5 | |
Atherosclerosis | 0.4 | 1 | -1.5 |
Atrial fibrillation | 1.5 | 1.6 | -0.07 |
Autism | 3.7 | 4.2 | -0.14 |
Barrett esophagus cancer | 0.2 | -0.2 | |
benign prostatic hyperplasia | 0.1 | 0.1 | |
Bipolar Disorder | 1.4 | 0.4 | 2.5 |
Brain Trauma | 0.5 | -0.5 | |
Carcinoma | 2.1 | 1.9 | 0.11 |
Celiac Disease | 2.3 | 1.9 | 0.21 |
Cerebral Palsy | 0.2 | 0.9 | -3.5 |
Chronic Fatigue Syndrome | 3.1 | 4.6 | -0.48 |
Chronic Kidney Disease | 1.1 | 0.1 | 10 |
Chronic Lyme | 0.5 | -0.5 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.5 | 0.5 | |
Chronic Urticaria (Hives) | 0.4 | 1.5 | -2.75 |
Coagulation / Micro clot triggering bacteria | 0.9 | 0.5 | 0.8 |
Colorectal Cancer | 3.4 | 0 | 0 |
Constipation | 1.6 | 1.6 | |
Coronary artery disease | 0.4 | 0.4 | |
COVID-19 | 6.3 | 8.7 | -0.38 |
Crohn's Disease | 4.1 | 2.9 | 0.41 |
cystic fibrosis | 0.3 | 0.5 | -0.67 |
deep vein thrombosis | 0.3 | 0.5 | -0.67 |
Depression | 6 | 2.7 | 1.22 |
Dermatomyositis | 0.2 | 0.2 | |
Eczema | 0.1 | 1.4 | -13 |
Endometriosis | 1.4 | 0.9 | 0.56 |
Epilepsy | 1.7 | 2 | -0.18 |
Fibromyalgia | 1.5 | 2 | -0.33 |
Functional constipation / chronic idiopathic constipation | 4.6 | 3 | 0.53 |
gallstone disease (gsd) | 1 | 1 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2 | 0.2 | 9 |
Generalized anxiety disorder | 0.3 | 0.5 | -0.67 |
Glioblastoma | 0.2 | -0.2 | |
Graves' disease | 1 | 1 | |
Halitosis | 0.5 | 0.2 | 1.5 |
Hashimoto's thyroiditis | 0.5 | 0.5 | 0 |
Hidradenitis Suppurativa | 0.2 | 0.2 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.2 | 0 | 0 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
hyperglycemia | 0.1 | 1 | -9 |
hypertension (High Blood Pressure | 1.6 | 2.1 | -0.31 |
Hypoxia | 1 | 1 | |
IgA nephropathy (IgAN) | 3.5 | -3.5 | |
Inflammatory Bowel Disease | 2.2 | 4.2 | -0.91 |
Insomnia | 0.6 | 0.5 | 0.2 |
Intelligence | 1 | 0.5 | 1 |
Intracranial aneurysms | 1.4 | 1.4 | |
Irritable Bowel Syndrome | 3.1 | 4 | -0.29 |
Liver Cirrhosis | 2.1 | 1 | 1.1 |
Long COVID | 4.8 | 3.6 | 0.33 |
Lung Cancer | 1.1 | 0.4 | 1.75 |
ME/CFS with IBS | 0.2 | 0.5 | -1.5 |
ME/CFS without IBS | 0.3 | 1.5 | -4 |
Menopause | 1 | 1 | |
Metabolic Syndrome | 4.2 | 5 | -0.19 |
Mood Disorders | 6.4 | 2.7 | 1.37 |
multiple chemical sensitivity [MCS] | 0.5 | 0.5 | |
Multiple Sclerosis | 1.3 | 4.1 | -2.15 |
Multiple system atrophy (MSA) | 0.4 | -0.4 | |
Neuropathy (all types) | 0.2 | 0.1 | 1 |
neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.8 | 1.4 | -0.75 |
Obesity | 3.6 | 2.2 | 0.64 |
obsessive-compulsive disorder | 6.2 | 1.6 | 2.88 |
Osteoarthritis | 0.7 | 0.4 | 0.75 |
Osteoporosis | 0.9 | 0.5 | 0.8 |
pancreatic cancer | 0.7 | 0.7 | |
Parkinson's Disease | 0.9 | 1.6 | -0.78 |
Polycystic ovary syndrome | 2.4 | 1.2 | 1 |
Premenstrual dysphoric disorder | 0.5 | -0.5 | |
primary biliary cholangitis | 1 | -1 | |
Psoriasis | 1.7 | 2.5 | -0.47 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.1 | 1.9 | 0.11 |
Rosacea | 0.4 | 0.4 | |
Schizophrenia | 2.9 | 0.4 | 6.25 |
scoliosis | 0.4 | -0.4 | |
Sjögren syndrome | 1.8 | 2 | -0.11 |
Sleep Apnea | 0.4 | 0.5 | -0.25 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 0.4 | |
Stress / posttraumatic stress disorder | 1.2 | 0.5 | 1.4 |
Systemic Lupus Erythematosus | 2.7 | 0.9 | 2 |
Tic Disorder | 1.9 | 0.5 | 2.8 |
Tourette syndrome | 0.5 | -0.5 | |
Type 1 Diabetes | 3.9 | 1.2 | 2.25 |
Type 2 Diabetes | 5.2 | 5.7 | -0.1 |
Ulcerative colitis | 0.9 | 5 | -4.56 |
Unhealthy Ageing | 2.7 | 0.6 | 3.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.